Preparing for a New Era in Alzheimer's Disease: Debating New Targeted Biomarkers and Therapeutic Approaches : Episode 3
Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease
The panel provides an overview of amyloid precursor protein (APP) and the generation of amyloid β (Aβ) peptides, Aβ42 and Aβ40, while also discussing which soluble or insoluble Aβ species (monomers, oligomers, protofibrils, or amyloid plaques) contribute to neuronal damage and the clinical manifestation of Alzheimer's disease.
EP: 1.Apolipoprotein E4 in Alzheimer’s Disease
EP: 2.Importance of Early Diagnosis of Alzheimer’s Disease
Now Viewing
EP: 3.Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease
EP: 4.Amyloid Cascade Hypothesis of Alzheimer’s Disease
EP: 5.Contribution of Multiple Pathways to the Development of Alzheimer’s Disease
EP: 6.Utilization of Neuroimaging in Alzheimer’s Disease
EP: 7.CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease
EP: 8.Utilization of APOE4 Genotype in Management of Alzheimer’s Disease
EP: 9.Alzheimer’s Disease Pipeline
EP: 10.The Future Outlook for Alzheimer’s Disease
What is amyloid precursor protein (APP)? How are amyloid β (Aβ) peptides, Aβ42 and Aβ40, generated?
Which soluble or insoluble species of Aβ (monomers, oligomers, protofibrils or amyloid plaques) contribute to neuronal damage and clinical manifestation of Alzheimer’s disease?
Related Videos
Related Content
